20 completed, 3 withdrawn, 2 unknown, 1 terminated. 8 Phase 4, 6 Not applicable, 6 Phase 1, 6 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 5, Unknown 2, Withdrawn 1 |
| Not applicable | 6 | Completed 4, Terminated 1, Withdrawn 1 |
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 6 | Completed 5, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
Follow atovaquone, proguanil drug combination: new trials by email Literature Review of atovaquone, proguanil drug combination trials Research Report on atovaquone, proguanil drug combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) Plasmodium falciparum, MK-7602, Artemether/lumefantrine - Malaria | Phase 1 | Completed | Merck Sharp & Dohme LLC | 16 | 2024-04-18 | 2025-01-13 |
| Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2) M5717 60 mg, Pyronaridine, Atovaquone-Proguanil - Malaria Infection | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 192 | 2023-11-28 | 2026-02-06 |
| Atoguanil BA Study Atoguanil, Malarone - Bioavailability | Phase 1 | Completed | Medicines for Malaria Venture | 16 | 2021-11-17 | 2022-05-05 |
| Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers Atovaquone / Proguanil 250/100 mg, Tegoprazan 50 mg, Esomeprazole 40 mg - Gastroesophageal Reflux Disease | Phase 1 | Completed | Seoul National University Hospital | 19 | 2020-11-25 | 2021-09-27 |
| A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI) atovaquone-proguanil - Plasmodium Falciparum | Not applicable | Withdrawn | U.S. Army Medical Research and Development Command | 2020-03-01 | 2020-05-08 | |
| Malarone Pharmacokinetics Under Simulated Physiologic Stressors of Deployment Malarone - Exercise, Pharmacokinetics | Phase 4 | Withdrawn | Walter Reed Army Institute of Research (WRAIR) | 2019-05-24 | 2021-04-30 | |
| Safety and Efficacy of NF135 CPS Immunization CPS-immunization, malaria challenge infection, P. falciparum NF135.C10, malaria challenge infection, P. falciparum NF54 - Malaria,Falciparum, Controlled Human Malaria Infection | Not applicable | Terminated | Radboud University Medical Center | 43 | 2019-04-01 | 2023-05-26 |
| Drug Combinations of Atovaquone-Proguanil (AP) With ACT Artesunate and Pyronaridine, Atovaquone Proguanil and Artesunate Pyronaridine, Atovaquone Proguanil and Artesunate Mefloquine - Plasmodium Falciparum Malaria (Drug Resistant) | Phase 4 | Unknown | Armed Forces Research Institute of Medical Sciences, Thailand | 252 | 2018-10-04 | 2021-03-02 |
| Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis Chloroquine-Azithromycin (CQ/AZ), Chloroquine (CQ), atovaquone-proguanil (Malarone®) - Malaria | Phase 2 | Withdrawn | U.S. Army Medical Research and Development Command | 2018-09-17 | 2020-02-27 | |
| Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2 Piperaquine (low dose), Piperaquine (high dose), Sulfadoxine pyrimethamine - Malaria,Falciparum, Gametocytes | Not applicable | Completed | Radboud University Medical Center | 24 | 2018-05-07 | 2020-07-07 |
| Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis atovaquone/proguanil 250mg/100mg (A/P), PfSPZ Challenge (NF54), NaCl 0,9% - Malaria | Phase 1 | Completed | University Hospital Tuebingen | 30 | 2016-11-28 | 2019-07-15 |
| Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis. Chloroquine, Atovaquone and Proguanil, Doxycycline - Rabies | Phase 4 | Completed | State University of New York - Upstate Medical University | 103 | 2016-11-11 | 2021-05-13 |
| Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1 Sulfadoxine-pyrimethamine (low dose), Piperaquine (low dose), Sulfadoxine-pyrimethamine (high dose) - Malaria | Phase 1 / Phase 2 | Completed | Radboud University Medical Center | 29 | 2016-06-01 | 2018-03-23 |
| DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria DSM265 400mg, Placebo to DSM265 400 mg, Plasmodium falciparum sporozoite challenge - Plasmodium Falciparum, Malaria | Phase 1 | Completed | Medicines for Malaria Venture | 22 | 2015-10-01 | 2021-01-13 |
| The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia atovaquone-proguanil, artesunate-atovaquone-proguanil - Malaria | Phase 4 | Unknown | Armed Forces Research Institute of Medical Sciences, Thailand | 205 | 2014-12-01 | 2021-03-02 |
| Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection CPS-immunization, malaria challenge infection, P. falciparum NF135.C10, malaria challenge infection, P. falciparum NF166.C8 - Malaria | Not applicable | Completed | Radboud University Medical Center | 40 | 2014-10-01 | 2016-02-23 |
| Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis CPS-immunization, Controlled Human Malaria Infection, chloroquine - Malaria | Not applicable | Completed | Radboud University Medical Center | 15 | 2014-06-01 | 2015-08-10 |
| Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis Chloroquine prophylaxis, Mefloquine prophylaxis, Immunization - Malaria, Plasmodium Falciparum | Not applicable | Completed | Radboud University Medical Center | 20 | 2012-01-01 | 2013-04-29 |
| Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria Malarone (atovaquone + proguanil combination), RIAMET (artemether + LUMEFANTRIN combination) - Malaria | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 317 | 2010-07-01 | 2015-12-09 |
| Weekly Dosing of Malarone ® for Prevention of Malaria Atovaquone Proguanil, Procedure - malaria challenge - Malaria | Phase 2 | Completed | U.S. Army Medical Research and Development Command | 35 | 2009-09-01 | 2013-11-25 |
Showing 20 of 26. Sign in to see all of them.
Malaria (20) · Malaria, Falciparum (12) · Asymptomatic Infections (1) · Gastroesophageal Reflux (1) · HIV Infections (1) · Infections (1) · Motor Activity (1) · Rabies (1)
Radboud University Medical Center (7) · U.S. Army Medical Research and Development Command (4) · Armed Forces Research Institute of Medical Sciences, Thailand (2) · Medicines for Malaria Venture (2) · Assistance Publique - Hôpitaux de Paris (1) · Jimma University (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck Sharp & Dohme LLC (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Novartis (1) · Pfizer (1) · Seoul National University Hospital (1) · State University of New York - Upstate Medical University (1) · University Hospital Tuebingen (1) · Walter Reed Army Institute of Research (WRAIR) (1)
Netherlands (7) · United States (4) · Cambodia (2) · Kenya (2) · Australia (1) · Burkina Faso (1) · Colombia (1) · Ethiopia (1) · France (1) · Germany (1) · Malawi (1) · South Korea (1) · The Gambia (1) · United Kingdom (1) · Zambia (1)
Mariusz Wojnarski, MD (2) · D.M. Burger, Dr. (1) · Gregory Deye, MD (1) · Jeffrey R Livezey, MD (1) · Lek Dysoley, MD (1) · Leo G Visser, MD, PhD (1) · Matthew BB McCall, MD PhD DTMH (1) · Nebreed Fesseaha, MD, Dean (1) · Olivier Bouchaud, MD, PhD (1) · Peter G Kremsner, Prof (1)
PMID 11832638, PMID 15838784, PMID 17213921, PMID 20299957, PMID 22052893, PMID 25396417, PMID 28363637, PMID 28903777, PMID 29482720, PMID 31146732, PMID 31743394, PMID 32239171, PMID 32938444, PMID 36897544, PMID 37024868, PMID 38918235, PMID 9455524